Skip to main content
    E

    Exelixis Inc (EXEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $67.10
    -1.90 (-2.75%)

    Market Cap: $16.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Exelixis Inc (EXEL) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Exelixis (EXEL) trades at 19.3x trailing earnings and 6.9x sales. Its P/E of 19.3x is above its 5-year median of 18.1x. Its forward P/E is 16.3x. The median P/E across 3 similar companies is 27.7x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 18.4% higher over the next year. Its free cash flow yield is 7.0%.

    MultipleValue
    P/E (trailing)19.3x
    Forward P/E16.3x
    Price to sales6.9x
    Price to book9.1x
    EV/EBITDA16.5x
    Price to FCF14.4x
    EV/FCF14.1x
    PEG2.3
    FCF yield7.0%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 0.5% above 19.2x, its P/S is 27.8% above 5.4x and its P/B is 122.0% above 4.1x.

    MultipleCurrent5-year median10-year median
    P/E19.3x18.1x19.2x
    P/S6.9x4.3x5.4x
    P/B9.1x3.2x4.1x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 114 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/E, its P/E ranged from 13.8x in 2018 to 59.6x in 2017.

    Year endPriceP/EP/SP/B
    2025$43.8314.2x5.2x5.7x
    2024$33.3016.4x4.4x4.2x
    2023$23.9926.7x4.2x3.3x
    2022$16.0419.6x3.2x2.1x
    2021$18.2818.1x4.0x2.7x
    2020$20.0732.4x6.4x3.4x
    2019$17.6216.2x5.6x3.3x
    2018$19.6713.8x6.9x4.8x
    2017$30.4059.6x20.0x33.4x
    2016$14.91N/A20.5x50.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About EXEL

    What is EXEL's forward P/E ratio?

    Exelixis has a forward P/E ratio of 16.3x.

    Is EXEL stock overvalued?

    GNG's valuation label for EXEL is Fairly valued. Its P/E of 19.3x compares with a median of 27.7x across 3 similar companies.

    What is EXEL's price to sales ratio?

    Exelixis has a price to sales ratio of 6.9x.

    What is Exelixis's average P/E ratio over 5 years?

    Exelixis's median P/E over the last 5 years is 18.1x, from 60 month-end values through Oct 2026.

    What is EXEL's PEG ratio?

    Exelixis has a PEG ratio of 2.3.